Cancer estrogen-dependent

Contraindications History of thromboembohc disorders, deep venous thrombosis, cerebral vascular disease, myocardial infarction, liver cancer, estrogen-dependent cancer, breast cancer, undiagnosed abnormal genital bleeding, or suspected pregnancy. 

Flueggine A MCF-7 (human breast cancer) estrogen-dependant phenotype 60 4 pM... 

WS-7528 [132147-69-4][VI] a nonsteroidal estrogen, is an isoflavone which has been isolated from Streptomjces sp. No. 7528 and is an estrogen agonist. It inhibits [3ff]-estradiol binding to its receptor in rat uterine cytosol at an inhibitor for 50% of the rats tested (IC q) concentration of 5.7 nM. It also induces the growth of estrogen-dependent human breast cancer cell line MCE-7 (7). 

A stmcturally related series of phenyfiiydrazones resulted ia the selection of compound A-007 [2675-35-6] (DEKK-TEC)(37) for the treatment of hormone-dependent tumors. A-007 is an antiestrogen that, ia contrast to tamoxifen, demonstrated inhibitory activity both ia the presence and absence of estradiol ia ZR-75-1 estrogen-dependent human breast cancer cells, and afforded more protection than tamoxifen ia the 7,12-dimethylbenz[i7]anthracene... 

TWADDLE G M, TURBOV J, LIU N, MURTHY s (1999) Tyrosine kinase inhibitors as antiprohferative agents against estrogen-dependent breast cancer cell line in vitro. JSurg Oncol. 70 ... 

YCUNG H J, DCERGE D R, KIMBERLY F A, ALLRED C D and HELFERICH W G (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62,2474-77. 

HRT should not be prescribed to women with a history of or active thromboembolic disease, breast cancer or estrogen-dependent neoplasm, pregnancy, liver disease, or undiagnosed vaginal bleeding. It also should not be used for the prevention or treatment of cardiovascular disease, cerebrovascular disease, or dementia.11... 

Boyan BD, Sylvia VL, Frambach T, Lohmann CE1, Died J, Dean DD, Schwartz Z (2003) Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative E1CC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 144(5) 1812—1824... 

The individual ability to produce estrogens becomes more relevant when analyzing estrogen-dependent diseases like osteoporosis and breast cancer. The incidence of breast cancer and fracture are inversely related. Cauley s data also illustrate this negative correlation (Cauley et al. 1996). 

Ju, Y.H., Allred, C.D., Allred, K.F., Karko, K.L., Doerge, D.R. and Helferich, W.G. (2001). Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice, J. Nutr., 131, 2957-2962. 

Initially characterized as an autoantigen in a human connective tissue disease [62]. May be associated with methylation induced gene silencing and heterochromatin [64,65,103]. Interacts with a component of DNA repair machinery [308]. Functions in estrogen dependent repression of Snail. Aberrant Snail expression results in loss of expression of the cell adhesion molecule E-cadherin, an event associated with invasive growth of breast cancers [309]. 

Apply patch twice weekly skin irritation. Breast tenderness, headache, edema. Risk of endometrial cancer diminished by concurrent progesterone use. Contraindicated in thromboembolic disorder, breast cancer, or estrogen-dependent malignancy. 

Twenty-four cyclopropyl compounds were screened for their antiproliferative activities, eighteen were found to be active and five appeared to be promising pure antiestrogens, superior to tamoxifen 128 not only in the treatment of the estrogen-dependent tamoxifen-responsive breast cancer patients, but also in the treatment of the estrogen-independent, tamoxifen non-responsive, breast cancer patients. 

Fig. 14 ZK-253 effects on tamoxifen-resistant breast cancer xenograft tumours. Estrogen-dependent MCF-7/TAM tumours were implanted on day 0 into one flank of 70 estrogen-and tamoxifen-supplemented nude mice. After tumours had reached approximately 25 mm in size (after about 22 days), mice were randomised into seven groups (10 mice each) three control groups (control tamoxifen, control vehicle or control ovariectomy without estradiol), and the fom treatment groups (ZK-703, ZK-253, raloxifene or fulves-trant) each at 10 mg/kg subcutaneously daily. Treatment was continued either until the end of the experiment or imtil tumoms reached a median of approximately 100 mm (larger tumours were observed in some mice). The tumours were then removed, snap frozen, and used for analysis of ER levels, a Xenograft tumour growth curves. Data are expressed as medians with interquartile ranges, b ERa levels. Data are expressed as mean with upper 95% Cl...

Contraindications Abnormal vaginal bleeding, active arterial thrombosis, blood dys-crasias, estrogen-dependent cancer, known or suspected breast cancer, thrombophlebitis or thromboembolic disorders, thyroid dysfunction... 

---